Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis

Bibliographic Details
Main Author: Giavina-Bianchi,Mara
Publication Date: 2021
Other Authors: Giavina-Bianchi,Pedro
Format: Report
Language: eng
Source: Einstein (São Paulo)
Download full: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082021000100501
Summary: ABSTRACT We report the cases of two adolescent siblings with severe atopic dermatitis, who, despite weighing approximately 40kg, presented a good response to dupilumab with the off-label dose for individuals aged 12 years and weighing 60kg. Both had already used cyclosporine, azathioprine, methotrexate and oral corticosteroids for long periods, plus topical treatments with no adequate disease control. Skin lesions were constant and widespread, with frequent skin infections and very poor quality of life, with numerous physical and psychosocial consequences, such as dropping out of school activities due to severe itching, appearance and bullying. They also showed delayed growth and development. In 2018, dupilumab, an immunobiological agent, was approved for treatment of moderate to severe atopic dermatitis in adults and, in 2019, extended to the 12-17-year age group. Although it had already been approved by the Brazilian Health Surveillance Agency, the 200mg presentation (indicated for the weight of patients) was not available, with no expected arrival date. Therefore, weighing the risks and benefits of the situation of both, we chose to treat them with an adult dose (loading dose of 600mg subcutaneously, and 300mg subcutaneously every 2 weeks) despite the low weight. So far, they have received eight injections, showing significant improvement of disease and quality of life. There were no major adverse effects, only worsening of allergic conjunctivitis in one of them. The patients and their family are very satisfied, and we believe that the therapy has been successful.
id IIEPAE-1_aff3018a2e6719e091b409e5e3b00aa2
oai_identifier_str oai:scielo:S1679-45082021000100501
network_acronym_str IIEPAE-1
network_name_str Einstein (São Paulo)
repository_id_str
spelling Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitisDermatitis, atopic/drug therapyConjunctivitis, allergicImmunosuppressive agentsSeverity of illness indexDermatologic agentsDupilumabAzathioprineAdolescentEfficacySafetyABSTRACT We report the cases of two adolescent siblings with severe atopic dermatitis, who, despite weighing approximately 40kg, presented a good response to dupilumab with the off-label dose for individuals aged 12 years and weighing 60kg. Both had already used cyclosporine, azathioprine, methotrexate and oral corticosteroids for long periods, plus topical treatments with no adequate disease control. Skin lesions were constant and widespread, with frequent skin infections and very poor quality of life, with numerous physical and psychosocial consequences, such as dropping out of school activities due to severe itching, appearance and bullying. They also showed delayed growth and development. In 2018, dupilumab, an immunobiological agent, was approved for treatment of moderate to severe atopic dermatitis in adults and, in 2019, extended to the 12-17-year age group. Although it had already been approved by the Brazilian Health Surveillance Agency, the 200mg presentation (indicated for the weight of patients) was not available, with no expected arrival date. Therefore, weighing the risks and benefits of the situation of both, we chose to treat them with an adult dose (loading dose of 600mg subcutaneously, and 300mg subcutaneously every 2 weeks) despite the low weight. So far, they have received eight injections, showing significant improvement of disease and quality of life. There were no major adverse effects, only worsening of allergic conjunctivitis in one of them. The patients and their family are very satisfied, and we believe that the therapy has been successful.Instituto Israelita de Ensino e Pesquisa Albert Einstein2021-01-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082021000100501einstein (São Paulo) v.19 2021reponame:Einstein (São Paulo)instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)instacron:IIEPAE10.31744/einstein_journal/2021rc6064info:eu-repo/semantics/openAccessGiavina-Bianchi,MaraGiavina-Bianchi,Pedroeng2021-05-06T00:00:00Zoai:scielo:S1679-45082021000100501Revistahttps://journal.einstein.br/pt-br/ONGhttps://old.scielo.br/oai/scielo-oai.php||revista@einstein.br2317-63851679-4508opendoar:2021-05-06T00:00Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)false
dc.title.none.fl_str_mv Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
title Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
spellingShingle Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
Giavina-Bianchi,Mara
Dermatitis, atopic/drug therapy
Conjunctivitis, allergic
Immunosuppressive agents
Severity of illness index
Dermatologic agents
Dupilumab
Azathioprine
Adolescent
Efficacy
Safety
title_short Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
title_full Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
title_fullStr Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
title_full_unstemmed Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
title_sort Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
author Giavina-Bianchi,Mara
author_facet Giavina-Bianchi,Mara
Giavina-Bianchi,Pedro
author_role author
author2 Giavina-Bianchi,Pedro
author2_role author
dc.contributor.author.fl_str_mv Giavina-Bianchi,Mara
Giavina-Bianchi,Pedro
dc.subject.por.fl_str_mv Dermatitis, atopic/drug therapy
Conjunctivitis, allergic
Immunosuppressive agents
Severity of illness index
Dermatologic agents
Dupilumab
Azathioprine
Adolescent
Efficacy
Safety
topic Dermatitis, atopic/drug therapy
Conjunctivitis, allergic
Immunosuppressive agents
Severity of illness index
Dermatologic agents
Dupilumab
Azathioprine
Adolescent
Efficacy
Safety
description ABSTRACT We report the cases of two adolescent siblings with severe atopic dermatitis, who, despite weighing approximately 40kg, presented a good response to dupilumab with the off-label dose for individuals aged 12 years and weighing 60kg. Both had already used cyclosporine, azathioprine, methotrexate and oral corticosteroids for long periods, plus topical treatments with no adequate disease control. Skin lesions were constant and widespread, with frequent skin infections and very poor quality of life, with numerous physical and psychosocial consequences, such as dropping out of school activities due to severe itching, appearance and bullying. They also showed delayed growth and development. In 2018, dupilumab, an immunobiological agent, was approved for treatment of moderate to severe atopic dermatitis in adults and, in 2019, extended to the 12-17-year age group. Although it had already been approved by the Brazilian Health Surveillance Agency, the 200mg presentation (indicated for the weight of patients) was not available, with no expected arrival date. Therefore, weighing the risks and benefits of the situation of both, we chose to treat them with an adult dose (loading dose of 600mg subcutaneously, and 300mg subcutaneously every 2 weeks) despite the low weight. So far, they have received eight injections, showing significant improvement of disease and quality of life. There were no major adverse effects, only worsening of allergic conjunctivitis in one of them. The patients and their family are very satisfied, and we believe that the therapy has been successful.
publishDate 2021
dc.date.none.fl_str_mv 2021-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082021000100501
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082021000100501
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.31744/einstein_journal/2021rc6064
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
dc.source.none.fl_str_mv einstein (São Paulo) v.19 2021
reponame:Einstein (São Paulo)
instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
instname_str Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron_str IIEPAE
institution IIEPAE
reponame_str Einstein (São Paulo)
collection Einstein (São Paulo)
repository.name.fl_str_mv Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
repository.mail.fl_str_mv ||revista@einstein.br
_version_ 1752129910952951808